Nothing Special   »   [go: up one dir, main page]

IN2014MN02338A - - Google Patents

Info

Publication number
IN2014MN02338A
IN2014MN02338A IN2338MUN2014A IN2014MN02338A IN 2014MN02338 A IN2014MN02338 A IN 2014MN02338A IN 2338MUN2014 A IN2338MUN2014 A IN 2338MUN2014A IN 2014MN02338 A IN2014MN02338 A IN 2014MN02338A
Authority
IN
India
Prior art keywords
inhibitors
relates
present
tec
members
Prior art date
Application number
Inventor
Alain Laurent
Yannick Rose
James B Jaquith
Original Assignee
Pharmascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2779184A external-priority patent/CA2779184A1/en
Priority claimed from CA2813299A external-priority patent/CA2813299A1/en
Application filed by Pharmascience Inc filed Critical Pharmascience Inc
Publication of IN2014MN02338A publication Critical patent/IN2014MN02338A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a novel family of inhibitors of protein kinases. In particular the present invention relates to inhibitors of the members of the Tec and Src protein kinase families.
IN2338MUN2014 2012-05-31 2013-05-28 IN2014MN02338A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA2779184A CA2779184A1 (en) 2012-05-31 2012-05-31 Protein kinase inhibitors
CA2813299A CA2813299A1 (en) 2013-04-17 2013-04-17 Protein kinase inhibitors
PCT/CA2013/000513 WO2013177668A1 (en) 2012-05-31 2013-05-28 Protein kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2014MN02338A true IN2014MN02338A (en) 2015-08-14

Family

ID=49672221

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2338MUN2014 IN2014MN02338A (en) 2012-05-31 2013-05-28

Country Status (11)

Country Link
US (1) US9796716B2 (en)
EP (1) EP2855484A4 (en)
JP (1) JP6175495B2 (en)
KR (2) KR101972990B1 (en)
CN (1) CN104379586B (en)
BR (1) BR112014029718A2 (en)
CA (1) CA2874211A1 (en)
HK (1) HK1208460A1 (en)
IN (1) IN2014MN02338A (en)
RU (1) RU2678767C2 (en)
WO (1) WO2013177668A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2833867A1 (en) * 2013-11-21 2015-05-21 Pharmascience Inc. Protein kinase inhibitors
CA2834528A1 (en) * 2013-11-26 2015-05-26 Pharmascience Inc. Protein kinase inhibitors
RU2674701C2 (en) * 2014-07-07 2018-12-12 Цзянсу Хэнжуй Медицин Ко., Лтд. Aminopiridazinove compounds as proteinkinase inhibitors
GB201508747D0 (en) 2015-05-21 2015-07-01 Univ Edinburgh Compounds
EP3337805A4 (en) * 2015-05-27 2019-04-03 Pharmascience Inc. Inhibitors of the tec kinase enzyme family
US10927087B2 (en) 2015-12-07 2021-02-23 Dic Corporation Method for producing polymerizable compound
WO2017134685A2 (en) * 2016-02-02 2017-08-10 Sun Pharma Advanced Research Company Limited Novel hydrazino compounds as btk inhibitors
CN109369654A (en) * 2018-11-20 2019-02-22 山东大学 1,3- bis- substituted-4-amino Pyrazolopyrimidines and its preparation method and application
CN111454268B (en) * 2019-01-18 2023-09-08 明慧医药（上海）有限公司 Cyclic molecules as inhibitors of bruton's tyrosine kinase
CN118414335A (en) * 2021-11-15 2024-07-30 微境生物医药科技(上海)有限公司 Compounds as Src inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
PL354241A1 (en) 1999-09-17 2003-12-29 Abbott Gmbh & Co.Kgabbott Gmbh & Co.Kg Kinase inhibitors as therapeutic agents
PT1212327E (en) * 1999-09-17 2004-01-30 Abbott Gmbh & Co Kg PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS
HUP0202263A3 (en) * 1999-12-27 2003-02-28 Japan Tobacco Inc Benzimidazole, indole and imidazo-pyridine derivatives and pharmaceutical compositions containing them
AUPR392301A0 (en) 2001-03-23 2001-04-26 University Of Newcastle Research Associates Limited, The Protein phosphatase inhibitors
CA2810339A1 (en) * 2001-08-10 2003-02-20 Novartis Ag Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
PL2081435T3 (en) 2006-09-22 2016-11-30 Inhibitors of bruton's tyrosine kinase
SG10202107066WA (en) * 2007-03-28 2021-07-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
US9144557B2 (en) * 2009-10-13 2015-09-29 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses
JP6139782B2 (en) * 2013-05-21 2017-05-31 チャンスー メドリューション リミテッド Substituted pyrazolopyrimidine compounds, and pharmaceutically acceptable salts thereof, and solvates, stereoisomers, and tautomers thereof, and pharmaceutical compositions containing them
CN103787839B (en) 2014-01-21 2015-12-02 苏州昊帆生物科技有限公司 The method of synthesis 2,3,4,5,6-Pentafluorophenol

Also Published As

Publication number Publication date
CN104379586B (en) 2018-01-16
US9796716B2 (en) 2017-10-24
BR112014029718A2 (en) 2017-06-27
KR20190043648A (en) 2019-04-26
US20150191473A1 (en) 2015-07-09
WO2013177668A1 (en) 2013-12-05
KR20150015527A (en) 2015-02-10
CA2874211A1 (en) 2013-12-05
HK1208460A1 (en) 2016-03-04
EP2855484A1 (en) 2015-04-08
RU2014145285A (en) 2016-07-20
RU2678767C2 (en) 2019-02-01
JP2015518009A (en) 2015-06-25
KR101972990B1 (en) 2019-04-26
EP2855484A4 (en) 2015-12-16
CN104379586A (en) 2015-02-25
JP6175495B2 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
IN2014MN02338A (en)
ZA201600648B (en) Novel pyrrolopyrimidine compounds as inhibitors of protein kinases
MX355728B (en) Kinase inhibitors.
HK1206298A1 (en) Compounds useful as inhibitors of atr kinase and combination therapies thereof atr
ZA201405140B (en) Disubstituted benzothienyl-pyrolotriazines and their use as fgfr kinase inhibitors
HK1212336A1 (en) Azaquinazoline inhibitors of atypical protein kinase
HK1215577A1 (en) Protein kinase inhibitors
MX343929B (en) Protein kinase inhibitors.
HK1202333A1 (en) Combination of kinase inhibitors and uses thereof
IN2015DN00127A (en)
EP2833889A4 (en) Protein kinase c inhibitors and uses thereof
PL2880035T3 (en) Novel pyrrolopyrimidine compounds as inhibitors of protein kinases
EP2858501A4 (en) TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
HK1205507A1 (en) Protein kinase inhibitors
HK1209726A1 (en) Protein kinase inhibitors
HK1210036A1 (en) Aminoisoquinoline derivatives as protein kinase inhibitors
GB201209458D0 (en) Novel compounds and their use as kinase inhibitors
GB201206048D0 (en) Novel compounds and their use as kinase inhibitors
MY168958A (en) Intermediates and processes for preparing compounds